Drug-maker AstraZeneca announced this week that the FDA is currently considering approving the needle-free option for home use. Called FluMist, the vaccine must be refrigerated and would be shipped in insulated packaging to people’s homes.
FluMist has been around for more than two decades and is approved for people ages 2 to 49 years old. It’s fallen in and out of favor over the years, including one period where a CDC advisory panel highlighted FluMist as the preferred flu vaccine for children. Later, its effectiveness was questioned, leading to a reformulation effort, STAT News reported.
AstraZeneca expects the FDA to make a decision on whether to allow home use of FluMist by Spring 2024. The convenience of home administration could increase the number of people who get a flu vaccine, said Ravi Jhaveri, MD, Chief of Infectious Diseases in the Department of Pediatrics at Northwestern University’s Feinberg School of Medicine.
Leave a reply